General
Preferred name
OPROZOMIB
Synonyms
PR-047 ()
ONX 0912 ()
ONX-0912 ()
P&D ID
PD013007
CAS
935888-69-0
Tags
drug candidate
nuisance
covalent binder
available
Drug indication
Haematological malignancy
Multiple myeloma
Hodgkin lymphoma
Solid tumour/cancer
Drug Status
investigational
Max Phase
Phase 1
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Oprozomib is an orally bioavailable derivative of , with similar biological action, i.e. inhibition of the chymotrypsin-like activity (a.k.a. β5 activity) of the proteasome . This is compound 58 in .
(GtoPdb)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Cell lines
3
Organisms
0
Compound Sets
14
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Nuisance compounds in cellular assays
ReFrame library
TargetMol Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
22
Molecular Weight
532.2
Hydrogen Bond Acceptors
9
Hydrogen Bond Donors
3
Rotatable Bonds
14
Ring Count
3
Aromatic Ring Count
2
cLogP
0.41
TPSA
148.25
Fraction CSP3
0.48
Chiral centers
4.0
Largest ring
6.0
QED
0.3
Structural alerts
1
Protein disruption
Proteosome inhibition
Nuisance compounds in cellular assays
Related compounds
Custom attributes
(extracted from source data)
Pathway
Proteases/Proteasome
Ubiquitination
Apoptosis
Autophagy
Metabolic Enzyme/Protease
Target
20S proteasome
Proteasome
MOA
Proteasome inhibitor
Source data
